Change search
ReferencesLink to record
Permanent link

Direct link
Evaluating tumor response of non-small cell lung cancer patients with 18F-fludeoxyglucose positron emission tomography: potential for treatment individualization
Stockholm University, Faculty of Science, Medical Radiation Physics (together with KI).ORCID iD: 0000-0002-7101-240X
RaySearch Laboratories AB, Sweden.
Karolinska Institutet, Sweden.ORCID iD: 0000-0001-6676-508X
Maastricht University Medical Center, The Netherlands.
Show others and affiliations
2015 (English)In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, Vol. 91, no 2, 376-384 p.Article in journal (Refereed) Published
Abstract [en]

Objective: To assess early tumor responsiveness and the corresponding effective radiosensitivity for individual patients with non-small cell lung cancer (NSCLC) based on 2 successive 18F-fludeoxyglucose positron emission tomography (FDG-PET) scans.

Methods and Materials: Twenty-six NSCLC patients treated in Maastricht were included in the study. Fifteen patients underwent sequential chemoradiation therapy, and 11 patients received concomitant chemoradiation therapy. All patients were imaged with FDG before the start and during the second week of radiation therapy. The sequential images were analyzed in relation to the dose delivered until the second image. An operational quantity, effective radiosensitivity, αeff, was determined at the voxel level. Correlations were sought between the average αeff or the fraction of negative αeff values and the overall survival at 2 years. Separate analyses were performed for the primary gross target volume (GTV), the lymph node GTV, and the clinical target volumes (CTVs).

Results: Patients receiving sequential treatment could be divided into responders and nonresponders, using a threshold for the average αeff of 0.003 Gy-1 in the primary GTV, with a sensitivity of 75% and a specificity of 100% (P<.0001). Choosing the fraction of negative αeff as a criterion, the threshold 0.3 also had a sensitivity of 75% and a specificity of 100% (P<.0001). Good prognostic potential was maintained for patients receiving concurrent chemotherapy. For lymph node GTV, the correlation had low statistical significance. A cross-validation analysis confirmed the potential of the method.

Conclusions: Evaluation of the early response in NSCLC patients showed that it is feasible to determine a threshold value for effective radiosensitivity corresponding to good response. It also showed that a threshold value for the fraction of negative αeff could also be correlated with poor response. The proposed method, therefore, has potential to identify candidates for more aggressive strategies to increase the rate of local control and also avoid exposing to unnecessary aggressive therapies the majority of patients responding to standard treatment.

Place, publisher, year, edition, pages
2015. Vol. 91, no 2, 376-384 p.
Keyword [en]
Response assessment, NSCLC, FDG PET, treatment adaptation, treatment individualization
National Category
Cancer and Oncology
Research subject
Medical Radiation Physics; Oncology; Radiation Physics
URN: urn:nbn:se:su:diva-108089DOI: 10.1016/j.ijrobp.2014.10.012ISI: 000348045400019OAI: diva2:753768
Available from: 2014-10-08 Created: 2014-10-08 Last updated: 2015-09-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Toma-Dasu, IulianaLazzeroni, MartaDasu, Alexandru
By organisation
Medical Radiation Physics (together with KI)
In the same journal
International Journal of Radiation Oncology, Biology, Physics
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 56 hits
ReferencesLink to record
Permanent link

Direct link